NCT05746182 Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
| NCT ID | NCT05746182 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Pancreatic Neuroendocrine Neoplasm |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-04-07 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2023-04-07 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective observational multi-center pilot study of germline testing for participants receiving care at University of California participating locations with a new or existing diagnosis of Pancreatic Neuroendocrine Neoplasms (PanNEN). This protocol is an extension of existing Genetic Testing Station efforts at University of California, San Francisco (UCSF)
Eligibility Criteria
Inclusion Criteria: 1. Histologically confirmed PanNEN. a. The diagnostic biopsy may have been taken from any site (primary or metastatic). 2. New and existing PanNEN participants will be eligible (any grade, any stage, any age \> 18 years). 3. Participants willing and able to comply with the study procedures. Exclusion Criteria: 1. Inability to provide informed consent. 2. For participants who have not had prior testing with a dedicated germline pane of at least 80 genes: 1. Inability to speak/read a language supported by the germline testing station (GTS). The supported languages currently include English, Korean, Japanese, Vietnamese, Russian, Tagalog, Farsi, Spanish, Cantonese, Mandarin, and Arabic). 2. Active hematologic malignancy. 3. History of allogenic bone marrow transplant or stem cell transplant.
Contact & Investigator
Emily Bergsland, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT05746182 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Neuroendocrine Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05746182 currently recruiting?
Yes, NCT05746182 is actively recruiting participants. Contact the research team at bryankhuong.le@ucsf.edu for enrollment information.
Where is the NCT05746182 trial being conducted?
This trial is being conducted at Los Angeles, United States, San Diego, United States, San Francisco, United States.
Who is sponsoring the NCT05746182 clinical trial?
NCT05746182 is sponsored by University of California, San Francisco. The principal investigator is Emily Bergsland, MD at University of California, San Francisco. The trial plans to enroll 300 participants.